Integrating experimentation and quantitative modeling to enhance discovery of beta amyloid lowering therapeutics for alzheimer's disease

5Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Drug discovery can benefit from a proactive-knowledge-attainment philosophy which strategically integrates experimentation and pharmacokinetic/pharmacodynamic (PK/PD) modeling. Our programs for Alzheimer's disease (AD) illustrate such an approach. Compounds that inhibit the generation of brain beta amyloid (Aβ), especially Aβ42, are being pursued as potential disease-modifying therapeutics. Complexities in the PK/Aβ relationship for these compounds have been observed and the data require an advanced approach for analysis. We established a semimechanistic PK/PD model that can describe the PK/Aβ data by accounting for Aβ generation and clearance. The modeling characterizes the in vivo PD (i.e., Aβ lowering) properties of compounds and generates insights about the salient biological systems. The learning from the modeling enables us to establish a framework for predicting in vivo Aβ lowering from in vitro parameters.

Cite

CITATION STYLE

APA

Lu, Y. (2012). Integrating experimentation and quantitative modeling to enhance discovery of beta amyloid lowering therapeutics for alzheimer’s disease. Frontiers in Pharmacology, 3 OCT. https://doi.org/10.3389/fphar.2012.00177

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free